$A retrospective study of isatuximab-pomalidomide-dexamethasone in relapsed/refractory systemic AL amyloidosis$

A retrospective study of isatuximab-pomalidomide-dexamethasone in relapsed/refractory systemic AL amyloidosis

Not available.

Saved in:

Bibliographic Details
Main Authors:	Sargam Rachit Vohra, Sriram Ravichandran, Darren Foard, Ana Martinez-Naharro, Lucia Venneri, Marianna Fontana, Carol J. Whelan, Philip N. Hawkins, Julian Gillmore, Helen J. Lachmann, Shameem Mahmood, Ashutosh D. Wechalekar
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2025-07-01
Series:	Haematologica
Online Access:	https://haematologica.org/article/view/12153
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Isatuximab–dexamethasone–pomalidomide combination effects on serum M protein and PFS in myeloma: Development of a joint model using phase I/II data
by: Antoine Pitoy, et al.
Published: (2024-12-01)

Long-Term Effectiveness and Safety of Isatuximab in Combination with Pomalidomide and Dexamethasone in a Japanese Patient with Refractory Multiple Myeloma and 1q21 Amplification: A Case Report
by: Takanori Yoshioka, et al.
Published: (2025-01-01)

Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
by: Enrica Antonia Martino, et al.
Published: (2025-03-01)

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
by: Andrew J. Yee, et al.
Published: (2025-03-01)

Revised renal stratification and progression models for predicting long-term renal outcomes in immunoglobulin light chain amyloidosis
by: Muhammad Umaid Rauf, et al.
Published: (2025-06-01)

Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis
by: Aaron S. Rosenberg, et al.
Published: (2025-08-01)

Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of “Double Refractory” Multiple Myeloma
by: AV Petrov, et al.
Published: (2017-07-01)

Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial
by: Salomon Manier, et al.
Published: (2025-03-01)

Effect of beta‐blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta‐analysis
by: Chun Shing Kwok, et al.
Published: (2024-12-01)

The role of pomalidomide in treatment of relapse and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2022-01-01)

Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)

Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report
by: Yu. E. Ryabukhina, et al.
Published: (2023-12-01)

PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
by: M. Yu. Frolov, et al.
Published: (2017-08-01)

Identification and removal of a cryptic impurity in pomalidomide-PEG based PROTAC
by: Bingnan Wang, et al.
Published: (2025-02-01)

Development and Validation of Pomalidomide Determination in Human Plasma by HPLC-MS/MS Method
by: T. N. Komarov, et al.
Published: (2020-11-01)

The Use of Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma in Patients with Renal Failure
by: IG Rekhtina, et al.
Published: (2018-10-01)

Pomalidomide for the management of relapsed and refractory multiple myeloma: a case report and review of literature
by: S. V. Semochkin
Published: (2015-10-01)

Subcutaneous administration of isatuximab in patients with multiple myeloma by an on-body delivery system: results of a nurse survey
by: Nuria Sánchez Avello, et al.
Published: (2025-06-01)

Vutrisiran in Transthyretin Amyloidosis
by: Ronald M. Witteles, MD, et al.
Published: (2025-09-01)

BRAIN-INVOLVED MULTIPLE MYELOMA: STABILITY ACHIEVED WITH BENDAMUSTINE-POMALIDOMIDE, RADIOTHERAPY AND DARATUMUMAB-BASED THERAPY
by: Bengisu Ece Duman, et al.
Published: (2024-12-01)

The effect of trimetazidine on cardiac haemodynamics and mitochondrial function in wild‐type transthyretin amyloidosis
by: Bertil Thyrsted Ladefoged, et al.
Published: (2025-06-01)

A SINGLE-CENTER REAL-LIFE EXPERIENCE WITH FIRST-LINE DARATUMUMAB, BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE (DARA-VCD) IN AL AMYLOIDOSIS
by: Metban Mastanzade, et al.
Published: (2024-12-01)

Comprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials
by: Muhammed Favas Karimbanathottathil, et al.
Published: (2024-12-01)

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
by: Yuhan Yan, et al.
Published: (2024-11-01)

Renal Response Criteria for Clinical Trials in Amyloid Light Chain Amyloidosis
by: Nelson Leung, et al.
Published: (2024-07-01)

FOXM1 down-regulation is a trigger of isatuximab-induced direct cell death in multiple myeloma cells with 1q+
by: Jiro Kikuchi, et al.
Published: (2025-07-01)

30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
by: Enrique M. Ocio, et al.
Published: (2024-11-01)

Case report: pomalidomide as maintenance after salvage autologous stem cell transplantation in a patient with relapsed multiple myeloma
by: S. V. Semochkin, et al.
Published: (2023-12-01)

Treatment pattern among patients with relapsed/refractory multiple myeloma (RRMM) who had received pomalidomide-based regimens in Taiwan
by: Chieh-Lin Jerry Teng, et al.
Published: (2024-12-01)

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)
by: Theo Leitner, et al.
Published: (2024-12-01)

Tracheobronchial amyloidosis
by: Khalil Jivraj, et al.
Published: (2014-01-01)

Tracheal amyloidosis
by: Ruwan Amaratunga, et al.
Published: (2014-01-01)

Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595
by: Nicola Sgherza, et al.
Published: (2025-06-01)

A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab
by: Daniel Thomas Jones, et al.
Published: (2025-03-01)

Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFRWT and EGFRT790M
by: Moustafa O. Aboelez, et al.
Published: (2022-12-01)

Hereditary transthyretin amyloidosis
by: T. A. Adyan, et al.
Published: (2020-01-01)

Amyloidosis of the Heart and Kidney
by: Horacio E. Adrogue
Published: (2022-09-01)

AMYLOIDOSIS HEART IN ELDERLY
by: L. I. Dvoretsky, et al.
Published: (2015-12-01)

Localized AL amyloidosis
by: Nelly A. Kashchavtseva, et al.
Published: (2025-01-01)